AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00L1C7XW0
2.24▼ 0.03 (-1.32%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
2.27
Day's Range
2.24 – 2.37
52-Week Range
2.04 – 14.86
Volume
42.4K
Avg Volume
175.1K
Share Statistics
Shares Outstanding
Employees
7
Exchange
XNAS
Listed
2018-06-07
Share count as of December 31, 2025

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)
What is Quantum Biopharma Ltd. Class B Subordinate Voting Shares's Market Cap?
Quantum Biopharma Ltd. Class B Subordinate Voting Shares's Market Cap is $8.7M, based on as-reported figures from SEC (XBRL) filings.
What is Quantum Biopharma Ltd. Class B Subordinate Voting Shares's Enterprise Value?
Quantum Biopharma Ltd. Class B Subordinate Voting Shares's Enterprise Value is $8.1M, based on as-reported figures from SEC (XBRL) filings.
What is Quantum Biopharma Ltd. Class B Subordinate Voting Shares's EV / EBITDA?
Quantum Biopharma Ltd. Class B Subordinate Voting Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Quantum Biopharma Ltd. Class B Subordinate Voting Shares's EBITDA?
Quantum Biopharma Ltd. Class B Subordinate Voting Shares's EBITDA is -$14.8M, based on as-reported figures from SEC (XBRL) filings.
What is Quantum Biopharma Ltd. Class B Subordinate Voting Shares's Net Debt?
Quantum Biopharma Ltd. Class B Subordinate Voting Shares's Net Debt is -$604.8K, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · QNTMAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Expenses
General and administrative
External research and development fees
Share-based payments
Depreciation and amortization
Impairment loss
Total operating expenses
Loss from operations
Interest income
Other income
Finance expense, net
Accretion and interest expense
Change in fair value of derivative liabilities and warrant liability
Realized (gain) on sale of digital assets
Realized (gain) on sale of investments
Realized loss on sale of finance receivables
Loss on issuance of convertible debt
Net loss
Net loss attributable to:
Equity owners of the Company